TherapeuticsMD, Inc. (TXMD)
Stock Price:
$1.61 USD
-0.44 (-21.46%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
After-hours: $1.68 +0.07 (4.35%) Aug 6, 7:58 PM
Key Info
| Market Cap |
437.41M |
| Revenue (ttm) |
57.95M |
| Net Income (ttm) |
-193.49M |
| Shares Out |
271.68M |
| EPS (ttm) |
-0.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$1.61 |
| Previous Close |
$2.05 |
| Change ($) |
-0.44 |
| Change (%) |
-21.46% |
| Day's Open |
1.79 |
| Day's Range |
1.58 - 1.85 |
| Day's Volume |
13,621,633 |
| 52-Week Range |
0.85 - 4.32 |
More Stats
| Market Cap |
437.41M |
| Enterprise Value |
519.52M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
271.68M |
| Float |
244.70M |
| EPS (basic) |
-0.76 |
| EPS (diluted) |
-0.76 |
| FCF / Share |
-0.62 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
82.86M |
| Short Ratio |
17.31 |
| Short % of Float |
33.87% |
| Beta |
2.15 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.55 |
| PB Ratio |
40.75 |
| Revenue |
57.95M |
| Operating Income |
-164.02M |
| Net Income |
-193.49M |
| Free Cash Flow |
-168.85M |
| Net Cash |
-82.11M |
| Net Cash / Share |
-0.30 |
| Gross Margin |
74.74% |
| Operating Margin |
-283.04% |
| Profit Margin |
-333.90% |
| FCF Margin |
-291.37% |
| ROA |
-45.51% |
| ROE |
-2,499.18% |
| ROIC |
-82.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
7 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.16*
(344.72% upside)
Low
1.25
Current: $1.61
High
13.00
Target: 7.16
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 49.65 | 16.10 | 16.78 | 19.36 | 20.14 | 15.03 | 8.78 | 3.82 | 2.09 | 1.24 |
| Revenue Growth | 208.38% | -4.04% | -13.32% | -3.9% | 34.05% | 71.23% | 129.85% | 82.84% | 68.14% | - |
| Gross Profit | 43.31 | 13.36 | 14.14 | 15.17 | 15.64 | 11.35 | 6.82 | 2.47 | 1.14 | 0.69 |
| Operating Income | -151 | -130 | -77.63 | -90.25 | -85.19 | -54.04 | -25.81 | -16.15 | -5.43 | -2.87 |
| Net Income | -176 | -133 | -76.93 | -89.88 | -85.08 | -54.22 | -28.42 | -35.12 | -12.91 | -2.87 |
| Shares Outstanding | 246 | 225 | 206 | 196 | 173 | 150 | 128 | 91.63 | 62.52 | 38.29 |
| Earnings Per Share | -0.72 | -0.59 | -0.37 | -0.46 | -0.49 | -0.36 | -0.22 | -0.38 | -0.21 | -0.07 |
| Operating Cash Flow | -166 | -107 | -76.16 | -69.14 | -79.04 | -45.52 | -20.77 | -12.74 | -4.97 | -2.84 |
| Capital Expenditures | -2.45 | -0.22 | -0.06 | -0.40 | -0.17 | -0.03 | -0.04 | -0.07 | -0.03 | -0.03 |
| Free Cash Flow | -168 | -107 | -76.22 | -69.54 | -79.21 | -45.55 | -20.81 | -12.80 | -5.00 | -2.87 |
| Cash & Equivalents | 161 | 162 | 127 | 132 | 64.71 | 51.36 | 54.19 | 1.55 | 0.13 | 0.42 |
| Total Debt | 204 | 73.38 | - | - | - | - | - | 3.59 | 2.35 | - |
| Net Cash / Debt | -42.95 | 88.23 | 127 | 132 | 64.71 | 51.36 | 54.19 | -2.04 | -2.22 | 0.42 |
| Assets | 266 | 212 | 143 | 142 | 73.73 | 59.08 | 62.02 | 5.93 | 1.44 | 1.20 |
| Liabilities | 257 | 114 | 13.32 | 14.98 | 10.67 | 10.69 | 7.32 | 7.36 | 3.15 | 0.23 |
| Book Value | 9.20 | 97.52 | 130 | 127 | 63.06 | 48.39 | 54.70 | -1.43 | -1.71 | 0.96 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
TherapeuticsMD, Inc. |
| Country |
United States |
| Employees |
348 |
| CEO |
Robert G. Finizio |
Stock Information
| Ticker Symbol |
TXMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: TXMD |
Description
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.